Grace Therapeutics, Inc. (GRCE) vs Impact Biomedical Inc. (IBO)

Grace Therapeutics, Inc. and Impact Biomedical Inc. are both Biotechnology companies. Grace Therapeutics, Inc. and Impact Biomedical Inc. are of similar size ($48.3M and $45.4M). Grace Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Impact Biomedical Inc. trades at 6.5×. Impact Biomedical Inc. has the higher net margin (2,254.3% vs 0.00%) and the higher return on invested capital (−22.8% vs −43.4%). Across the 15 metrics below, Impact Biomedical Inc. leads on 8 and Grace Therapeutics, Inc. on 7.

Valuation

Metric GRCE IBO Biotechnology median
P/E n/m 6.45 7.88
P/S 183.34 17,528.61 11.47
P/B 0.76 43.78 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 116.74 17,756.07 10.73
Earnings yield (55.66%) 15.50% (28.84%)
Free cash flow yield (27.88%) (0.09%) (23.03%)

Profitability

Metric GRCE IBO Biotechnology median
Gross margin 0.00% (1,111.43%) 65.16%
Operating margin 0.00% (14,600.00%) 0.00%
Net margin 0.00% 2,254.29% 0.00%
Free cash flow margin 0.00% (1,451.43%) 0.00%
Return on equity (36.19%) 24.01% (57.72%)
Return on assets (33.74%) 4.41% (49.22%)
Return on invested capital (43.36%) (22.81%) 0.00%

Growth

Metric GRCE IBO Biotechnology median
Revenue growth (TTM) 1,286.81% — 5.64%
EPS growth (last fiscal year) 40.51% 83.48% —
Revenue growth, 5-year CAGR (22.91%) — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric GRCE IBO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.47 0.16 4.73
Net debt to EBITDA 1.53 0.00 0.96

Dividend

Metric GRCE IBO Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric GRCE IBO Biotechnology median
Market cap 45.44m 48.27m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack